Skip to main content

Medical Education Nursing Contact Us

Home
Find a Doctor
Find a Location
Services
Patients and Visitors
MyChart Login

Search

Services

Spartanburg Regional Healthcare System is dedicated to providing patient-centered care to communities we serve. Explore the wide range of services we offer.

Frequently Visited Services

Behavioral Health
Breast Health
Cancer
Emergency
Heart

Hospice
Imaging
Immediate Care
Maternity
Pharmacy

Rehabilitation
Spine
Sports Medicine Institute
Telehealth
Weight Loss

Patients and Visitors

Whether you’re seeking care or visiting a loved one, Spartanburg Regional Healthcare System is here for you. Our compassionate team provides the resources and support you need so you can focus on what is important.

Patients

Advance Directives
Chaplain Services
ER Wait Times
Language Services
Medical Records
MyChart Help and Information
Patient Rights
Planning Discharge
Pre-admission Testing (PAT)
Recognize Your Caregiver
When to Go Where

Visitors

Directions & Maps
Gift Shops
Hotel Information
Visitor Guidelines
Volunteer
Wireless Internet

Financial

Bill Pay
Financial Assistance Program
Insurance Information
Pricing Policies
No Surprises Act

Find a Doctor
Find a Location
Services
Patients and Visitors
MyChart Login
Medical Education
Nursing
Contact Us

Search

Menu

Search

Clinical Research Trials

Search by Name

(-) Oncology
Clear all filters

Status

Closed
Accepting Participants
Complete

Disease Site

(-) Oncology
Symptom Management & Cancer Control
Thoracic Cancer
Breast Cancer
Hematologic Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Precision Medicine & Rare Tumors
Cancer Care Delivery Research (CCDR)
Cardiology
Phase 1
Head & Neck Cancer
Cutaneous & Sarcoma Cancer
Gynecologic Cancer
Other
Neurologic Cancer
Nephrology
Neo-Natal
Trauma
Wound Healing - Infectious Disease

Study Type

Oncology

Oncology

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma (S1826)
Closed
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers (NRG-CC008)
Accepting Participants
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma (A071702)
Accepting Participants
A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients With Resectable Brain Metastases (BN-012)
Accepting Participants
AMG 510 (pINN) Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (Amgen 20190135 Subprotocol E)
Closed
AMG 510 in Combination with Carboplatin and Pemetrexed or with Docetaxel in Subjects with NSCLC with KRAS p.G12C Mutation (Amgen Subprotocol F)
Accepting Participants
Assessment Of Cognitive Function In Breast Cancer And Lymphoma Patients Receiving Chemotherapy At Pre-Treatment, Post-Treatment, At Six Month Follow-Up, And Long-Term Follow-Ups (URCC 10055)
Closed
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/antiPD-L1 Immunotherapy in a Community Oncology Setting (URCC-21038)
Accepting Participants
Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer
Complete
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps, FORTE (NRG-CC005)
Accepting Participants
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials (EAQ202)
Accepting Participants
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (A081801)
Closed
Mepitel Film for the Reduction of Radiation Dermatitis in Breast Cancer Patients Undergoing Post-Mastectomy Radiation Therapy: A Randomized Phase III Clinical Trial (A221803)
Accepting Participants
Myopenia and Mechanism of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study (WF-1806)
Accepting Participants
NCI Community Oncology Research Program (NCORP) Tissue Procurement Protocol: An NCI Cancer MoonshotSM Study
Accepting Participants
Optimizing Endocrine Therapy Adherence Through Motivational Interviewing and Text Interventions (GETSET) (A191901)
Accepting Participants
Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or Fewer Brain Metastases From Small Cell Lung Cancer (NRG-CC009)
Closed
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma (S1608)
Closed
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) (S1900A)
Closed
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer (EA5163/ S1709)
Accepting Participants
Screening Mammogram (TMIST) (EA1151)
Accepting Participants
Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast (ES2018-07)
Accepting Participants
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers (S1815)
Closed
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer, SOLARIS (A021703)
Closed
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment (EMERALD-2)
Complete
Dose Dense Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations (A031701)
Accepting Participants
Germ Cell Tumor, Pediatric and Adult Patients (COG AGCT1531)
Accepting Participants
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)(NRG-GU009)
Accepting Participants
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE) (NRG-GU010)
Accepting Participants
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (A031803)
Accepting Participants
Uterine Cervix or Vaginal Cancer, Newly Diagnosed (NRG-GY006)
Closed
Vulva, Advanced Squamous Cell, Locally Advanced (GOG-0279)
Closed
Nasopharynx, Based on Biomarker EBV DNA (NRG-HN001)
Closed
A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects With Chronic Lymphocytic Leukemia (AZ ASSURE)
Closed

Hematologic Cancer

Leukemia, Acute Promyelocytic (EA9131) Observational
Closed
Leukemia, Chronic Lymphocytic (CLL), Untreated Older Patients (A041702)
Closed
Leukemia, Chronic Lymphocytic (CLL), Untreated Younger Patients (EA9161)
Closed
Leukemia, Chronic Lymphocytic (PCYC-1134M), Registry
Closed
Multiple Myeloma, Untreated, Stem Cell Transplant Not Planned (54767414MMY3019)
Closed
Multiple Myeloma: 1st Line Therapy (E1A11)
Closed
Myelofibrosis or Essential Thrombocythemia (INCB-MA-MF-401) Registry
Closed
Lymphoma, Diffuse Large B-Cell, Relapsed or Refractory (1562-201)
Complete
Plasmacytoma of the Bone (A061402)
Complete
Study of Lenalidomide/ Ixazomib/ Dexamethasone/ Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM (AFT-41)
Closed

Precision Medicine & Rare Tumors

Lymphoma, Hodgkin (CA209655) Observational
Closed
Leukemia, Chronic Myeloid (S1712)
Complete
Lymphoma, Diffuse Large B-Cell, Treatment Naïve (DB102-02)
Complete
Lymphoma, Mantle Cell, Previously Treated (AFT-32)
Complete
Non-small Cell Lung Cancer NSCLC, EGFR Mutant (A081105)
Closed
Solid Tumors (eFT508-0010)
Closed
Solid Tumors or Lymphomas; MATCH (EAY131)
Closed
Melanoma, Stage III-IV BRAF Mutant (S1320)
Closed
Merkel Cell Carcinoma, Advanced (A091605)
Closed
Merkel Cell Carcinoma, Resected (EA6174)
Closed
Advanced Cancer, ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor (QUILT-3.055)
Closed

Phase 1

Multiple Myeloma, Refractory to Lenalidomide (A061202)
Closed
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreak 100) (Amgen 20170543)
Closed
AMG 510 (pINN) Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (Amgen 20190135 Subprotocol C)
Closed
Advanced Solid Tumors w/ FGF/FGFR Aberrations (TPU-TAS-120-101)
Closed

Thoracic Cancer

A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination With Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (Mermaid-1)
Closed
A Randomized Phase III Trial of Induction/ Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC (S1914)
Accepting Participants
Adenoma and Second Primary Prevention Trial (S0820)
Closed
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab (NRG-LU005)
Closed
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK) (S1827)
Accepting Participants
Non-small Cell Lung Cancer (NSCLC), Metastatic (NRG LU-002)
Complete
Non-small Cell Lung Cancer ALCHEMIST (A151216)
Accepting Participants
Non-small Cell Lung Cancer, Previously Treated (SWOG Lung-Map)
Closed
Phase 1/2 Study of Stereotactic Body Radiation Therapy (SBRT) With or Without GC4711 for Early Stage, Centrally Located or Large Non-Small Cell Lung Cancer (NSCLC)(GRECO-1)
Closed
Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy. (MERMAID-2)
Closed
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
Accepting Participants

Symptom Management & Cancer Control

All Disease Sites; Health Disparities (DCP-001)
Accepting Participants
Blinded Reference Set for Multicancer Early Detection Blood Tests (A212102)
Accepting Participants
Effect of Treatment on Work Experience in Patients With Stage I-III Prostate Cancer (WF-1802 PCW)
Closed
EROS: Engendering Reproductive Health within Oncologic Survivorship (E1Q11)
Closed
Lung Cancer, Survivors (RELAX) (WF01213)
Closed
NCI COVID-19 in Cancer Patients, NCCAPS Study (NCI COVID, N-CCaPS)
Closed
Non-small Cell Lung Cancer NSCLC; Stages I-II; African-American, (WF01414) Observation
Closed
Survivors, Work Ability in Young Adult Survivors (WF 10217)
Closed
Wireless Transcutaneous Electrical Nerve Stimulation (TENS) for Chemotherapy-Induced Peripheral Neuropathy: A Phase II Clinical Trial (URCC 19085 TENS)
Closed
Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue (URCC 18007)
Accepting Participants
Colorectal Cancer, Cognitive Impairment (URCC 16092)
Complete
Ovarian, Fallopian Tube, and Primary Peritoneal, Diet & Physical Activity (GOG-0225)
Complete

Breast Cancer

A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer (S1706)
Accepting Participants
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases (S2007)
Accepting Participants
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial (A011801)
Accepting Participants
Breast or Gynecologic Cancer, Improving Sexual Desire (NRG-CC004)
Closed
HER2 Negative Primary Breast Cancer, gBRCA1/2 Mutations and High Risk (NSABP B-55)
Closed
High Risk, Node-Positive, Early Stage (NSABP B-58)
Closed
High-Risk; Hormone Receptor-Positive and HER2/Neu Negative (S1207)
Closed
Triple Receptor-Negative Breast Cancer (S1418/BR006)
Closed
Triple-Negative Basal-Like Breast Cancer (EA1131)
Closed
Breast Cancer Survivors, Cognitive Impairment, (REMEMBER) (WF 97116)
Complete
Breast Cancer, Young Women, Pregnancy Outcomes (POSITIVE) (A221405)
Complete

Cancer Care Delivery Research (CCDR)

A patient will not be eligible for participation in this study if any of the following criteria apply. Primary brain tumor or active brain metastasis Not recovered to less than or equal to Grade 1 toxicities (except Grade 2 alopecia or neuropathy) associ
Accepting Participants
Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment
Accepting Participants
Implementation and Effectiveness Trial of HN-STAR (WF-1805CD)
Accepting Participants
Assessment of Financial Difficulty in Participants With Chronic Lymphocytic Leukemia and Multiple Myeloma (A231602CD)
Closed
Colon or Rectal Cancer, Stage I-III, Financial Burden Assessment (EAQ162CD)
Closed
Implementing Palliative Care: Learning Collaborative vs. Technical Assistance (URCC18110CD - ENABLE)
Closed
Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy (NRG-CC007CD)
Closed
Leukemia, Acute Lymphocytic (ALL), Adolescent & Young Adult (ACCL16N1CD)
Closed
Supportive Care Service (WF 1803CD)
Closed
Understanding the Impact of Drug Shortages on Oncology Care Delivery (URCC18004CD)
Closed

Cutaneous & Sarcoma Cancer

A Phase II Study of Biomarker Driven Early Discontinuation of Anti-PD-1 Therapy in Patients With Advanced Melanoma (PET-Stop)
Accepting Participants
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma (A091902)
Closed

Gastrointestinal Cancer

A Randomized Phase II Study De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE) (EA2182)
Accepting Participants
The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing The Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients With Locally Advanced Rectal Cancer (A022104)
Accepting Participants
Liver, Non-resectable, (RESIN) Registry
Closed
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer (EA2165)
Closed
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)(NRG GI005)
Closed
Pancreatic Adenocarcinoma, Metastatic (ABI-007-PANC009)
Complete
Pancreatic Adenocarcinoma, Metastatic (NLG2104)
Complete

Genitourinary Cancer

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer (S1806)
Accepting Participants
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study (A031704)
Accepting Participants
Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial (NRG LU007)
Accepting Participants
A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery (RTOG-3506 STEEL)
Closed
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy (EA8143)
Closed
Phase II Study of Bladder-SparIng ChemoradiatioN With MEDI4736 (Durvalumab) in Clinical Stage III, Node PosItive BladdeR CancEr (EA8185 - INSPIRE)
Closed
Prostate, Unfavorable Intermediate or Favorable High Risk (RTOG 0924)
Closed
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors (A031102)
Closed
Urothelial, Muscle Invasive and Locally Advanced (A031501)
Closed

Head & Neck Cancer

A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer (NRG HN005)
Accepting Participants
A Trial Testing Chemo Mouthpiece Device and Best Supportive Care Against Best Supportive Care Only for Symptoms of Oral Mucositis in Patients Receiving Chemotherapy (CHEM-01)
Closed
Head and Neck Cancer, Advanced (NRG-HN004)
Closed
Head and Neck, Non-Metastatic, Reduce Severe Oral Mucositis (GTI-4419-301)
Closed

ABOUT US

Board of Trustees
Community Health
Diversity and Inclusion
Media Policy
Mission and Vision

News - Discover Health
Policies
Quality
Social Media Guidelines
Spartanburg Regional Healthcare System History
Spartanburg Regional Healthcare System Museum
The Spartanburg Community

RESOURCES

Careers
Employees
Price Transparency
Information for Vendors
Integrity Hotline

Medical Staff Services
Project SEARCH
Safety and Awareness
Sponsorship
Health Library
Transfer Center
Transportation Services
Volunteer

IMPORTANT LINKS

Apella Health Management
Discover Health
Regional HealthPlus
Southeastern Health Partners
Spartanburg Regional Foundation

© 2024 Spartanburg Regional Healthcare System. All Rights Reserved.